TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03718091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M6620
Description: M6620 is a drug designed to inhibit the ATR enzyme. Inhibiting ATR may block how cancers repair their naturally damaged DNA, handle cancer cell stress, and maintain cancer cell life and health.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M6620
Description: M6620 is a drug designed to inhibit the ATR enzyme. Inhibiting ATR may block how cancers repair their naturally damaged DNA, handle cancer cell stress, and maintain cancer cell life and health.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M6620
Description: M6620 is a drug designed to inhibit the ATR enzyme. Inhibiting ATR may block how cancers repair their naturally damaged DNA, handle cancer cell stress, and maintain cancer cell life and health.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M6620
Description: M6620 is a drug designed to inhibit the ATR enzyme. Inhibiting ATR may block how cancers repair their naturally damaged DNA, handle cancer cell stress, and maintain cancer cell life and health.
Study: NCT02117687

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboxymethylcellulose 0.5%/glycerin 0.9%
Description: 1-2 drops OPTIVE FUSION™ (carboxymethylcellulose 0.5%/glycerin 0.9%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.
Study: NCT03718091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M6620
Description: M6620 is a drug designed to inhibit the ATR enzyme. Inhibiting ATR may block how cancers repair their naturally damaged DNA, handle cancer cell stress, and maintain cancer cell life and health.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M6620
Description: M6620 is a drug designed to inhibit the ATR enzyme. Inhibiting ATR may block how cancers repair their naturally damaged DNA, handle cancer cell stress, and maintain cancer cell life and health.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M6620
Description: M6620 is a drug designed to inhibit the ATR enzyme. Inhibiting ATR may block how cancers repair their naturally damaged DNA, handle cancer cell stress, and maintain cancer cell life and health.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M6620
Description: M6620 is a drug designed to inhibit the ATR enzyme. Inhibiting ATR may block how cancers repair their naturally damaged DNA, handle cancer cell stress, and maintain cancer cell life and health.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M6620
Description: M6620 is a drug designed to inhibit the ATR enzyme. Inhibiting ATR may block how cancers repair their naturally damaged DNA, handle cancer cell stress, and maintain cancer cell life and health.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M6620
Description: M6620 is a drug designed to inhibit the ATR enzyme. Inhibiting ATR may block how cancers repair their naturally damaged DNA, handle cancer cell stress, and maintain cancer cell life and health.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M6620
Description: M6620 is a drug designed to inhibit the ATR enzyme. Inhibiting ATR may block how cancers repair their naturally damaged DNA, handle cancer cell stress, and maintain cancer cell life and health.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M6620
Description: M6620 is a drug designed to inhibit the ATR enzyme. Inhibiting ATR may block how cancers repair their naturally damaged DNA, handle cancer cell stress, and maintain cancer cell life and health.
Study: NCT03730402

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: utilizing local anesthetic to perform a regional block under laparoscopic guidance

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exparel 266 milligram Per 20 ML Injection
Description: utilizing local anesthetic to perform a regional block under laparoscopic guidance

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: placebo injection of saline
Study: NCT03664349

Intervention type: DEVICE
Intervention: SuperEar9000
Description: Handheld hearing amplifier, not FDA regulated.
Study: NCT00323011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fragmin, 5-Fluorouracil, Folinic Acid, irinotecan, bevacizumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fragmin, 5-Fluorouracil, Folinic Acid, irinotecan, bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fragmin, 5-Fluorouracil, Folinic Acid, irinotecan, bevacizumab
Study: NCT02358291

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open discectomy
Description: The open discectomy, will be performed under general anesthesia in the prone position with horizontal. The level of the spine indicated for surgical treatment will be identified with the aid of fluoroscopy. An incision is made about the dorsal disc level involved with dissection of the paravertebral muscles on the side of disc herniation. After laminectomy and resection of part of the yellow ligament, partial discectomy is done under direct vision.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open discectomy
Description: The open discectomy, will be performed under general anesthesia in the prone position with horizontal. The level of the spine indicated for surgical treatment will be identified with the aid of fluoroscopy. An incision is made about the dorsal disc level involved with dissection of the paravertebral muscles on the side of disc herniation. After laminectomy and resection of part of the yellow ligament, partial discectomy is done under direct vision.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: microendoscopic discectomy
Description: Microendoscopic discectomy combines standard lumbar microsurgical techniques with endoscope, enabling surgeons to successfully address free-fragment disc pathologic factors and lateral recess stenosis.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: microendoscopic discectomy
Description: Microendoscopic discectomy combines standard lumbar microsurgical techniques with endoscope, enabling surgeons to successfully address free-fragment disc pathologic factors and lateral recess stenosis.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transforaminal endoscopic lumbar discectomy
Description: transforaminal endoscopic lumbar discectomy removes the intervertebral disc portion through the intervertebral foramen

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transforaminal endoscopic lumbar discectomy
Description: transforaminal endoscopic lumbar discectomy removes the intervertebral disc portion through the intervertebral foramen
Study: NCT01714791

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Patients exercise at a heart rate corresponding to 65% of baseline Vo2peak. Each exercise training session takes 40-60 minutes. Exercise time is apportioned as follows: 42% on the treadmill, 33% on the circle ergometer and 25% on the arm cranking device. All patients exercise under close supervision 3 days per week for a total duration of 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Patients exercise at a heart rate corresponding to 65% of baseline Vo2peak. Each exercise training session takes 40-60 minutes. Exercise time is apportioned as follows: 42% on the treadmill, 33% on the circle ergometer and 25% on the arm cranking device. All patients exercise under close supervision 3 days per week for a total duration of 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic treatment
Description: Patients receive 4 osteopathic treatments (OT). OT is performed in week 4, 5, 8 and 12 postoperative. Depending on what is found in the patient, treatments consist mostly of one or more of the following approaches:~* Structural High Velocity Low Amplitude-techniques.~* Muscle Energy Techniques.~* General osteopathic mobilisations.~* Functional techniques (Sutherland-, Jones-techniques,...) including inhibition techniques.~* Fascia techniques.~* Soft tissue- and connective tissue techniques.~* Neurovisceral and neurolymphatic reflex techniques.~* Fluidal techniques (lymphatic manipulative techniques,...).~* Visceral manipulations.~* Neurocranial and viscerocranial techniques.
Study: NCT02117687

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium hyaluronate 0.18%
Description: 1-2 drops VISMED® Multi (sodium hyaluronate 0.18%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.
Study: NCT02469571

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Winclove 607
Description: multispecies probiotic

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02761967

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Women from the 20th week of moderate physical exercise performed in water character designed following the guidelines in the SWEP method will end in week 37 of gestation. After the postpartum period, women begin a program based on postpartum recovery exercises Fitness Low Pressure method 12-week, 3 days a week, in sessions of 60 minutes.
Study: NCT03950921

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Safety Display
Description: Digital display of catheter and pressure injury information in patient hospital room
Study: NCT03689309

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High Flow Oxygen SBT
Description: The patient is disconnected from the ventilator and remains 30 minutes without support but high flow oxygen delivered through a dedicated piece that is usually connected on tracheotomy.
Study: NCT02453815

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: non-cardiac surgery
Description: all surgical procedures except cardiac
Study: NCT01955707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: natalizumab
Description: Administered as described in the treatment arm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo
Study: NCT02453815

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: non-cardiac surgery
Description: all surgical procedures except cardiac

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: arterial catheter
Description: arterial catheter
Study: NCT02372734

Intervention type: OTHER
Intervention: Pediatric Quality of Life (Peds QL) Survey
Description: The subjects will be administered the Peds QL survey. Children will also have a parental section for parental response. This is NOT an interventional study.

Intervention type: OTHER
Intervention: Pediatric Quality of Life (Peds QL) Survey
Description: The subjects will be administered the Peds QL survey. Children will also have a parental section for parental response. This is NOT an interventional study.
Study: NCT01193257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orteronel
Description: Orteronel tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Prednisone tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Orteronel Placebo
Description: Orteronel placebo-matching tablets
Study: NCT03776370

Intervention type: PROCEDURE
Intervention: Preserve the left colonic artery
Description: Preservation of left colonic artery in rectal cancer surgery.

Intervention type: PROCEDURE
Intervention: The left colonic artery is not preserved
Description: The left colonic artery was dissected in rectal cancer surgery.
Study: NCT01793870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tab carvedilol 25 mg
Description: Carvedilol 25 mg immediate release tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tab carvedilol 25 mg
Description: Carvedilol 25 mg immediate release tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tab carvedilol 25 mg
Description: Carvedilol 25 mg immediate release tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tab carvedilol 25 mg
Description: Carvedilol 25 mg immediate release tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tab carvedilol 6.25 mg
Description: Carvedilol 6.25 mg immediate release tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Powder carvedilol up to 2.5 mg
Description: Carvedilol up to 2.5 mg isotopically enriched drug substance powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Powder carvedilol up to 2.5 mg
Description: Carvedilol up to 2.5 mg isotopically enriched drug substance powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Powder carvedilol up to 2.5 mg
Description: Carvedilol up to 2.5 mg isotopically enriched drug substance powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Powder carvedilol up to 2.5 mg
Description: Carvedilol up to 2.5 mg isotopically enriched drug substance powder
Study: NCT01456624

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Megace
Description: 800mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Megace
Description: 800mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW-ES(B)
Description: 625mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW-ES(B)
Description: 625mg
Study: NCT01237951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palifermin
Description: 60 micrograms/kg infused as an IVP (by vein) over 15-30 seconds Days -12 to -10 and Days 0 to +2 as an outpatient.~60 micrograms/kg by vein on Days -13 to -11 and on Days 0, +1 and +2 as in inpatient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 8 mg IV twice a day by vein over 15 minutes Days -9 through -2 as an outpatient or inpatient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1875 mg/m\^2 IV (75 mg/ m2 bolus followed by 1800 mg/m\^2 over 3 hours) on Day -8 and Day -3 as an outpatient or inpatient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: 32 mg/m2 test dose with PKs as outpatient before Day -12, or as an inpatient on Day -10.~Busulfan AUC 4,000 by vein on Days -8 to -5 as an outpatient or inpatient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 60 mg/m\^2 IV on Days -3 and -2 over 30 minutes on both days as an outpatient or inpatient.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant
Description: On Day 0, stem cells returned to body by vein over 30-60 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 5 mcg/kg/day subcutaneously beginning on Day +5 and continuing until neutrophil recovery is documented.
Study: NCT03033329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single intravenous doses of MRX-4
Description: Intravenous single escalating doses of MRX-4

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Single intravenous doses of placebo
Description: Intravenous single doses of placebo to match MRX-4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multiple intravenous doses of MRX-4
Description: Multiple ascending doses of MRX-4 given intravenously twice daily for 10 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Multiple intravenous doses of placebo
Description: Multiple doses of placebo to match MRX-4 given intravenously twice daily for 10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single dose of intravenous and oral MRX-4
Description: Crossover single dose of intravenous and oral MRX-4 given on Day 1 and Day 4
Study: NCT01817790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Description: Nasal spray formulation (200 mcg/day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle for Fluticasone propionate aqueous nasal spray
Study: NCT02803333

Intervention type: OTHER
Intervention: No Intervention
Description: No intervention
Study: NCT02789267

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular dietary support
Description: Systematic and regular dietary support after radiotherapy
Study: NCT03010371

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Psychotherapy
Description: Positive Psychotherapy (PP) is designed to treat cancer survivors with moderate/severe adaptation difficulties after completing cancer treatments (Ochoa et al., 2010). The objectives are the facilitation and promotion of post-traumatic growth and quality of life, and the reduction of emotional distress (anxiety, depression and post-traumatic symptoms). Secondary consequences of this psychological improvement is a better transition to daily life and the restoration of a good psychosocial functioning (labor reincorporation, adherence to treatments and follow-up, and the adoption of healthy lifestyles). The program consists of twelve sessions of 90 minutes per week in a closed group (5 to 7 participants). Each session focuses on the different topics and tasks defined in the Positive Psychotherapy for cancer survivors (Ochoa et al., 2010).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Online Psychotherapy
Description: The Positive Online Psychotherapy (POP) is based on the PP program, but being adapted to an online version. Patients in this experimental condition will have access to a secure virtual platform (supervised and dependent from the Catalan Health Department). The POP consists of twelve weekly sessions of 90 minutes, in a closed-group format (5-7 participants). Patients have a simultaneous group-connection to the online platform, together with a clinical psychologist who lead the tasks according to the focuses of each session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: The Cognitive Behavioral Therapy (CBT) is based on the Cognitive Behavioral Stress Management (Antoni, 2003) and the training program derived from it, Breast Cancer Stress Management and Relaxation Training (B-SMART) by Antoni Michael (2003). In its Spanish version, it is a 10-session therapy aimed to reduce cancer-related emotional distress, facilitating adjustment to illness and greater quality of life. Stress management and relaxation techniques help patients to identify their own stress responses and learn alternative ways of thinking and acting in response to the demands they perceive as highly stressful.
Study: NCT01802164

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A non-absorbable composite mesh (Ethicon Physiomesh)
Description: To compare prophylactic mesh implantation to conventional abdominal wall closure in patients undergoing emergency laparotomy for peritonitis.
Study: NCT00109590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Didanosine, enteric-coated
Description: once daily
Study: NCT02125214

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Target Controlled Infusion system (Orchestra Base Primea, Fresenius, France)
Description: Intravenous induction with propofol using the pharmacokinetic model by Schnider et al. The initial cerebral concentration will be 0.5 µg ml-1, which will be increased stepwise by 1.0 µg ml-1 until 2.5 µg ml-1, and then by 0.5 µg ml-1 until loss of consciousness
Study: NCT00109590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Didanosine, enteric-coated
Description: once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Didanosine, enteric-coated
Description: once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Description: twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Description: twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Description: single-dose at the onset of labor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Description: single-dose at the onset of labor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Description: single-dose at the onset of labor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidovudine
Description: twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidovudine
Description: twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidovudine
Description: twice daily
Study: NCT04208113

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School teacher training /.b
Description: The intervention is a multi-level, multi-component complex intervention. It consists of a school teacher training programme and the .b-programme to be delivered to pupils 11-15 years in the schools.~The school teacher training programme consists of three parts: 1) the establishment of own mindfulness practice by participation in the MBSR programme and sustaining mindfulness with a regular formal daily practice; 2) completion of the four days .b residential course, and 3) completion of the 3x2-days seminars on relational competences and implementation issues regarding teaching .b .~The .b programme consists of well-described, weekly 40-60 minutes classroom sessions over 10 weeks. All the sessions have a specific theme, associated teachers' notes, power points and animations. The .b programme can only be delivered with fidelity by a trained .b teacher.
Study: NCT04049409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMAB809
Description: CMAB809 will be administered by IV infusion at a single dose of 6mg/kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab will be administered by IV infusion at a single dose of 6mg/kg.
Study: NCT03006614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVB

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EPI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DDP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEM

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: H

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CTX

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: T
Study: NCT01904981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beta-blocker-Atenolol 50mg, PO(peroral), Once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blocker-Valsartan 80mg, PO(peroral), Once daily
Study: NCT02862353

Intervention type: BIOLOGICAL
Intervention: blood sample
Description: 15 ml of blood